Information derived from the complete genome sequence of Mycobacterium tuberculosis makes it possible to develop a range of new vaccine candidates. Strategies currently under investigation include construction of whole cell live attenuated mycobacterial vaccines, as well as the use of individual antigens delivered by a variety of subunit vaccination procedures. Fundamental questions associated with the rational design, preclinical testing, and future application of new tuberculosis vaccines are reviewed.
No takes yet. Share an insight, caveat, or question.
Douglas Young (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: